Oct 12 close
Inhibrx Biosciences fell 1.62 percent to $95.42 on October 5 after its second-quarter loss of $2.34 per share missed consensus. The company also updated its corporate presentation to highlight pipeline progress, and analysts maintained a Moderate Buy consensus despite varied valuation views. A separate comparison piece set Inhibrx alongside peer Connect Biopharma on dividends, analyst recommendations, institutional ownership and valuation.
INBX closed at $90.53, down 4.7%, with its one-month return at -17.2% while the six-month return stands at 16.9%. The close sits between its 50-day average of $103.38 and 200-day average of $91.36, reflecting a mixed trend. The GekkoIndex reads 66, placing the stock in the Accumulation zone, and the price sits 37.6% below the Gekko Fair Value of $144.98.
The next earnings report is scheduled for 13 November 2026, 31 days out and beyond a typical 20-trading-day holding window; the prior report showed an average absolute reaction of 7.5% and a -10.2% move after the last print. Over the last 90 days, 14 open-market insider purchases totaling $5,498,379 have been recorded, alongside one billionaire holder and one trailblazer holder. Seasonally, the next 20 trading days have averaged a 43.2% move over 5 years, with gains in 4 of those years, worth noting alongside the stock's typical 20-day move of 13%.
Written by AI from the Oct 12, 2026 close and checked automatically against the figures on this page.
Inhibrx Biosciences scores 5 supportive, 1 mixed and 0 headwinds across the 6 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
5 supportive1 mixed0 headwinds
Averages disagree
Close $90.53 sits between the 50-day ($103.38) and 200-day ($91.36) averages, or the averages disagree.
See the chart66, Accumulation
Reading 66 is in the Accumulation zone.
See the GekkoIndex37.6% below
Price is 37.6% below Gekko Fair Value (more than 5% below).
See fair valueLeans bullish
Last 90 days: 14 open-market insider purchases.
See smart moneyReports in 32 days
Next report Nov 13, 2026, 32 days away — outside a typical 20-trading-day hold.
See earnings+43.2% on average
From this point in the calendar, the next 20 trading days averaged +43.2% over 5 years, rising in 4 of them.
See seasonalityA description of current data, not a recommendation. How this page works
Inhibrx Biosciences closed at $90.53 on Oct 12, 2026, +158.7% over the past year, inside a 52-week range of $28.16 to $155.29.
Use the left and right arrow keys to read daily values.
Put INBX on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Inhibrx Biosciences develops biologic drug candidates that are still in clinical testing rather than on the market. Its work centers on protein engineering methods it has built itself, which it uses to design therapies with adjustable multivalent structures. Among its candidates are INBRX-109 and INBRX-106, both engineered so that the number of binding sites can be tuned for a given target in order to produce a suitable agonist effect.
The company operates as a biopharmaceutical research and development organization, with its activities focused on advancing this pipeline through clinical trials rather than selling approved products commercially at this stage.
Inhibrx Biosciences was founded by Brendan P. Eckelman on January 8, 2024, and its headquarters are in La Jolla, California. The company's shares are listed on the NASDAQ under the ticker INBX.
Inhibrx Biosciences’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 66, in the Accumulation zone, up 1.5 points over five sessions.
Up 1.5 points over five sessions.
Reading for Oct 12, 2026
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 38 | +0.8% | +6.1% | ||
| Accumulation (current zone) | 247 | +0.3% | +4.9% | ||
| Neutral | 338 | +2.6% | +9.6% | ||
| Distribution | 52 | +1.0% | +1.7% | ||
| Selling | 6 | Too few readings yet | |||
Average INBX share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Accumulation readings averaged +2.2% over 20 days. Past behaviour doesn’t guarantee future results.
Accumulation zone: Institutional interest building. About the five zones →
Inhibrx Biosciences trades 37.6% below Gekko Fair Value of $144.98, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what Inhibrx Biosciences shares are worth, recalculated every trading day.
$144.98
Gekko Fair Value, Oct 10, 2026
37.6% Undervalued
At the end of Aug 2026 the price was 38.7% below the estimate.
Insiders filed 14 open-market purchases in Inhibrx Biosciences worth $5.50M, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
$5.50Min 14 open-market purchases
| Filed | Insider | Type | Value |
|---|---|---|---|
| Sep 28 | Lappe Mark director, officer: Chief Executive Officer | Purchase | $329K |
| Sep 28 | Lappe Mark director, officer: Chief Executive Officer | Purchase | $305K |
| Sep 28 | Lappe Mark director, officer: Chief Executive Officer | Purchase | $217K |
| Sep 28 | Lappe Mark director, officer: Chief Executive Officer | Purchase | $148K |
| Sep 23 | Kayyem Jon Faiz director | Purchase | $500K |
From Form 4 filings, dated to when each was filed.
No trades in INBX were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Inhibrx Biosciences has been buying back its own shares.
From company filings.
2of the funds Gekko tracks hold INBX.
Inhibrx Biosciences reports on Nov 13, 2026 (32 days away), and beat the EPS estimate in 2 of its last 8 reports.
Nov 13, 2026
32 days away
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Aug 13, 2026 | −$2.34 est −$2.28 | — | −10.2% |
| May 14, 2026 | −$2.15 est −$1.20 | — | −7.9% |
| Mar 19, 2026 | −$2.11 est −$1.63 | — est $1.11M | −11.3% |
| Nov 14, 2025 | −$2.28 est −$2.08 | — | +3.7% |
| Aug 13, 2025 | −$1.85 est −$2.92 | $1.30M | +9.2% |
| May 14, 2025 | −$2.80 est −$2.55 | $100K | +6.6% |
| Nov 14, 2024 | −$2.84 est −$1.48 | — | −10.5% |
| Aug 13, 2024 | $125.48 est −$1.52 | $100K | +0.4% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Analysts’ average 12-month price target for Inhibrx Biosciences is $266.67, +194.6% from the last close, from 3 firms rating the stock in the last 90 days.
Each firm’s latest rating in the last 90 days: 3 firms.
| Date | Firm | Target | vs price |
|---|---|---|---|
| Sep 9 | H.C. Wainwright | $245 | +170.6% |
| Sep 8 | LifeSci Capital | $230 | +154.1% |
| Aug 24 | H.C. Wainwright | $245 | +170.6% |
| Aug 21 | Stifel Nicolaus | $325 | +259.0% |
| Aug 14 | LifeSci Capital | $230 | +154.1% |
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Over the next 20 trading days from Oct 10, Inhibrx Biosciences averaged +43.2% across the last 5 years, rising in 4 of them.
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | +11.3% | 4 of 5 |
| Next 10 trading days | +20.9% | 4 of 5 |
| Next 15 trading days | +42.5% | 4 of 5 |
| Next 20 trading days | +43.2% | 4 of 5 |
| Next 30 trading days | +40.0% | 4 of 5 |
For scale, INBX’s typical 20-trading-day move in either direction is about 13%.
Inhibrx Biosciences’s market cap is $1.33B and revenue of $0 over the last twelve months.
3 headlines about Inhibrx Biosciences from the past week, newest first, each linking to the publisher.
Inhibrx Biosciences’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| AMGNAmgen | Neutral | 25.5% below |
| GILDGilead Sciences | Neutral | 4.2% above |
| MRNAModerna | Neutral | 62.7% above |
| NTRANatera | Neutral | 10.3% above |
| IQVIQVIA | Neutral | 8.4% above |
| UTHRUnited Therapeutics | Neutral | 14.4% below |
A peer links to its own page where one exists.
Inhibrx Biosciences’s market cap is $1.33B at the Oct 12, 2026 close of $90.53, with 14.72M shares outstanding.
The consensus analyst 12-month price target for Inhibrx Biosciences is $266.67, +194.6% from the last close. Of the 3 firms that rated the stock in the last 90 days, 3 rate it a buy, 0 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
On Gekko’s estimate Inhibrx Biosciences is undervalued: the Oct 12, 2026 close of $90.53 is 37.6% below Gekko Fair Value of $144.98. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
Inhibrx Biosciences is expected to report on Nov 13, 2026 (32 days away). Analysts expect earnings of −$2.45 per share on revenue of $1.90M. Inhibrx Biosciences beat the earnings estimate in 2 of its last 8 reports, moving 7.5% on average across the report.
Inhibrx Biosciences’s 52-week high is $155.29 and its 52-week low is $28.16; it closed at $90.53 on Oct 12, 2026, +158.7% over the past year.
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 5 of the 6 items with data read as supportive (gekkoindex, fair value, smart money, earnings risk and seasonality), 1 as mixed (trend). The checklist is a description of current data, not a recommendation.
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,408 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.Type a ticker or company name. Press Esc to close.